Carrick Therapeutics
↗Dublin, Ireland
Carrick Therapeutics is a clinical-stage biopharmaceutical company dedicated to building an innovative portfolio of first-in-class treatments for aggressive and resistant forms of cancer. The company focuses on targeting the molecular pathways that drive tumor growth and resistance, particularly through the development of selective cyclin-dependent kinase (CDK) inhibitors.
Headquartered in Dublin with a significant presence in Boston and Oxford, Carrick leverages a global network of academic and industry partners to accelerate its drug development programs. Its lead candidate, samuraciclib, is a first-in-class oral CDK7 inhibitor currently being evaluated in multiple Phase 2 trials for breast cancer and other solid tumors.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:Pre-revenue
Founded:2015
Ownership:private
Status:operating
FUNDING
Stage:Series C
Total Raised:$245M
Investors:ARCH Venture Partners, GV (Google Ventures), Pfizer, Lightstone Ventures, Rosetta Capital, Cambridge Innovation Capital, Evotec
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2 (moving to Phase 3 in 2026)
Modalities:Small molecule, Glue-degrader
Active Trials:5
Trial Phases:Phase 1: 2 | Phase 2: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Carrick Therapeutics Inc. (US), Carrick Therapeutics UK Limited
Key Partnerships:Pfizer (Strategic investment and clinical collaboration for samuraciclib + Ibrance), Roche (Collaboration using MORPHEUS platform for samuraciclib + giredestrant), Menarini Group (Collaboration for samuraciclib + elacestrant combination)
COMPETITION
Position:Emerging
Competitors:Syros Pharmaceuticals, Recursion Pharmaceuticals, Relay Therapeutics, AstraZeneca, Eli Lilly
LEADERSHIP
Key Executives:
Tim Pearson - CEO
Stuart McIntosh - Chief Medical Officer
Scientific Founders:Ed Ainscow, Elaine Sullivan, Ash Bahl
Board Members:Steven Gillis (ARCH Venture Partners), Tim Pearson
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Carrick Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.